Article
The FDA has approved Visudyne (verteporfinfor injection) therapy for the treatment of predominantly classic subfovealchoroidal neovascularization (CNV) caused by pathologic myopia and presumedocular histoplasmosis.
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.